SynthesisScientific reports2025
Extended Spectrum Beta-Lactamase-Producing Bacterial Clones in West Africa: A Systematic Review and Meta-Analysis from a One Health Perspective.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Epidemiological trends in antibiotic resistant Klebsiella pneumoniae in healthcare settings in Burkina Faso: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Antimicrobial resistance among clinical Enterobacterales isolated from humans in Senegal: a systematic review and meta-analysis from 1987 to 2022.BMC infectious diseases · 2026Pooled it
- Role of extended-spectrum β-lactamase (ESBL) genes in the dissemination of β-lactam resistance within aquatic environments: mechanisms, persistence, and one health implications.World journal of microbiology & biotechnology · 2026Review
- Multidrug-resistant Enterobacterales causing wound infections in Ibadan, Nigeria: Phenotypic resistance and detection ofIJID regions · 2026Article
- Molecular epidemiology and antimicrobial resistance of extended-spectrum beta-lactamases-producingJAC-antimicrobial resistance · 2026Article
- Prevalence and Genomic Insight of Extended-Spectrum β-Lactamase-ProducingFoods (Basel, Switzerland) · 2026Article
- Whole-genome sequencing reveals high-risk ESBL and carbapenemase-producing Enterobacterales on maternity ward surfaces in Cameroon.Scientific reports · 2026Article
- Molecular Epidemiology of theMicroorganisms · 2026Article
- Systematic Review and Meta-Analysis of Extended-Spectrum Beta-Lactamase-Producing (ESBL)Antibiotics (Basel, Switzerland) · 2026Review
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
- Legal, ethical and moral dilemma of human cloning: the conflict between technological progress and human dignity.Frontiers in medicine · 2026Review
- Drug Resistance Patterns and Pathogen Distribution in Patients with Urinary Tract Infection in Suzhou, China: A Five-Year Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
- Genomic Diversity and Extended-SpectrumInternational journal of microbiology · 2026Article
- Genomic characterization, antimicrobial resistance, and virulence profiling ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Extended-spectrum beta-lactamase (ESBL)-producing bacteria are associated with life-threatening infections with limited treatment options worldwide. In this review, we assess the circulating ESBL-producing bacterial clones from human, animal, and environmental sources in West Africa, through a One Health approach. A systematic search in PubMed, Scopus, and Web of Science identified 485 records, with 38 studies analysed. Data were organized thematically and pooled prevalence estimates calculated through a random-effects meta-analysis. Results showed a 16.8% (95% CI [12.1; 22.1]) prevalence of ESBL-producing bacteria, with Escherichia coli (64%) being the most frequently detected species. Humans were the most affected (20.4%), followed by animals (12.8%) and the environment (9.3%). Among the 153 identified bacterial clones, ST10, ST410, ST58, ST155, ST4684, ST2178, and ST37, found majorly in E. coli, occurred across multiple sources, suggesting cross-sectoral transmission. The blaCTX-M gene, prevalent with several fluoroquinolone and aminoglycoside resistance genes, was often on conjugative IncF plasmids (50.0%), suggesting high horizontal transmission potential. The emerging ESBL gene, GES (1.2%) was also detected in Pseudomonas aeruginosa. The findings reinforce the need for robust antimicrobial resistance monitoring and intervention strategies in West Africa. A regional One Health-based approach is necessary to curtail the spread of resistant bacterial clones and safeguard the efficacy of available treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.